FDAnews
www.fdanews.com/articles/73346-data-from-vytorin-tirla-of-patients-with-type-2-diabetes-presented-at-ada

Data From Vytorin Tirla of Patients With Type 2 Diabetes Presented at ADA

June 14, 2005

Results from a new prespecified analysis of the VYVA (VYtorin Versus Atorvastatin) trial involving a subgroup of 428 patients with Type 2 diabetes were consistent with the overall VYVA trial announced earlier this year.

In this new analysis, results showed that Vytorin provided 56 percent reduction in LDL ("bad') cholesterol across the dosing range in these patients as compared to 46 percent reduction seen in patients taking Lipitor.

At the most commonly used starting doses, 59 diabetic patients taking Vytorin 10/20 mg, reduced their LDL cholesterol by 53 percent as compared to the 35 percent reduction seen in the 46 patients taking Lipitor 10 mg. This difference was similar to the results seen in the overall study population.